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Abstract 
Type 2 diabetes (T2D) is characterized by lacking production of insulin and impaired insulin sensitivi-
ty. Despite the availability of antidiabetic drugs on the market, exploration of new therapeutic drugs for 
treating T2D from nature remains necessary. This review provides insights on the potential of helminths and 
helminth derived products to modulate immune response for treating T2D. We discussed several helminths that 
are under investigation in animal models for treating T2D namely Schistosoma mansoni, Nippostrongylus 
brasiliens, Litomosoides sigmodontis, and Strongyloides stercoralis. Finally, application of Schistosoma man-
soni soluble egg antigens (SEA) in T2D treatment is also reviewed.  
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Abstrak 
[Evaluasi helminth untuk pengobatan Diabetes Tipe 2 - sebuah tinjauan pustaka] 
Diabetes tipe 2 (T2D) dicirikan oleh produksi insulin yang tidak mencukupi, maupun akibat gangguan 
sensitivitas insulin. Terlepas dari banyaknya obat antidiabetes yang telah tersedia di pasaran, eksplorasi 
sumber obat baru dari alam tetaplah diperlukan. Review ini menguraikan potensi cacing dan produk 
turunannya dalam memodulasi respon imun untuk mengatasi T2D. Dalam review ini kami mendiskusikan 
beberapa spesies cacing yang sedang diujikan pada hewan coba untuk dikembangkan guna mengatasi T2D 
seperti Schistosoma mansoni, Nippostrongylus brasiliens, Litomosoides sigmodontis, dan Strongyloides 
stercoralis. Selain itu, literatur review juga difokuskan  pada penggunaan antigen telur terlarut (soluble eggs 
antigens, SEA) dari Schistosoma mansoni sebagai alternatif pengobatan T2D.. 
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INTRODUCTION 
Diabetes mellitus refers to chronic metabolic 
disorders as shown by elevated plasma glucose level 
because of pancreatic functional impairment to syn-
thesize insulin, decreased insulin sensitivity, or 
combination of both factors.(1) Diabetes is diagnosed 
when the concentration of fasting blood glucose is 
more than 126 mg/dl (7.0 mmol/l) or when the 
concentration of 2-hours after meal blood glucose is 
more than 200 mg/dl (11.1 mmol/l).(2) Both the 
World Health Organization and International 
Diabetes Federation  estimated that diabetes current-
ly affects more than 420 million people world wide. 
(3, 4) The incidence rate of diabetes perpetually rising 
in the past decade and could potentially reach to 592 
million within 15 years.(5) 
Diabetes is classified into four general 
categories  namely type 1 diabetes (T1D), type 2 
diabetes (T2D), gestasional diabetes mellitus, and 
specific types of diabetes caused by genetics, 
diseases of the exocrine pancreas, and drug or 
chemical-induced diabetes.(1) T1D is an 
autoimmune disease since the immune system rec-
ognizes and attacks host β-cells pancreas, which  
consequently influence the capacity of β-cells to 
synthesize insulin.(6) On the other hand, T2D is due 
to inefficient production of insulin by β-cells or 
decreased insulin sensitivity.(3) The prevalence of 
T2D among adult patients is higher at around 90% 
to 95% compared to T1D.(7) 
To date, therapies on T2D focus mainly on 
decreasing the level of blood glucose and 
Hemoglobin A1c (HbA1c).(8)  Clinical studies 
however, underlined the continuous progression of 
diabetes, despite the efforts to lower the level of 
HbA1c.(9) Furthermore, some defects such as 
elevated lipolysis, decreased glucose uptake, and 
increased hepatic glucose production were detected 
as other implications of the pathogenesis of T2D.(9) 
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Therefore, future therapy on T2D should prohibit 
the development of this disease by targeting the 
pathogenic disturbances (i.e., maintaining β-cell 
function and increasing insulin sensitivity). To apply 
this concept, multidrug therapy with varied 
mechanisms of action might be introduced right 
away at the beginning of the therapy, while at the 
same time,  new T2D drugs are developed.(10) 
Recently, helminths obtain a limelight as 
future treatment for T2D due to the immuno-
modulating effect of these parasitic worms in their 
hosts by inducing type 2 immune response. This 
immune response is characterized by the expression 
of the cytokines interleukin (e.g. IL-4, IL-5, IL-9, 
and IL-13), production of T helper 2 (Th2) cells, and 
elevation  level of immunoglobulin (Ig) E, eosino-
philia and mastocytosis.(11) A previous study shows 
the correlation between immune response and glu-
cose metabolism due to helminth infection, especial-
ly in preserving insulin sensitivity.(11) Furthermore, 
helminth-derived product such as Schistosoma man-
soni soluble egg antigens (SEA) and lacto-N-
fucopentaose III (LNFPIII) may also be sources of 
potential therapeutic agents for treating T2D since 
they increase sensitivity to insulin and maintain glu-
cose-metabolism homeostasis.(12)  
Nature provides untapped sources of genetic 
diversity and biochemical richness for health and 
therapeutics purposes.(13) Among these genetics 
richness, helminths could serve as valuable source 
for antidiabetic treatments, however, their true 
potentials have not been unraveled. This review 
discusses progress that has been made with respect 
to apply helminth as treatments for T2D. In order to 
obtained the most relevant and updated references, 
we used PubMED database and searched based on 
key words focusing on diabetes type 2, helminth, 
and soluble egg antigens. From these relevant 
references, we elaborated the type 2 immune 
responses due to helminths infections and linked 
with the impact on T2D.  
 
TYPE 2 DIABETES 
Type 2 diabetes (T2D) arises when pancreat-
ic β-cells synthesize minute amounts of insulin or 
when target cells display reduced insulin sensitivity 
(insulin resistance).(14) In many cases, T2D can only 
be detected after emerging complications such as 
heart diseases,  retinopathy, nephropathy, or neurop-
athy.(15) It is estimated that 8.5% of the adult 
population worldwide live with diabetes and this 
percentage is envisioned to elevate in the near 
future.(3)  
The lifestyle management (e.g. a balanced 
diet, sufficient physical activities, no smoking, and 
avoid overweight and obesity) holds a valuable key 
to prevent the emerging of T2D.(16, 17) Furthermore, 
sufficient medication is an integral aspect to balance 
the homeostasis of the body. Nowadays, metformin 
is the first line therapy to treat T2D patients since 
this drug significantly reduce the level of HbA1C 
by 1.5% and fasting plasma glucose by 20%.(18) 
Besides, metformin does not lead to side effects 
such as weight gain and hypoglycemia.(19) Drugs 
among the class of Sulfonylureas, e.g. 
glibenclamide and glimepiride are the alternative 
for metformin since they effectively reduce the 
level of HbA1C levels, but could lead to 
hypoglycemia.(20) DeFronzo and co-workers 
reported pathogenesis in T2D patients is not solely 
caused by pancreatic β-cells, but is also induced by 
other tissues such as liver, muscle, fat cells, 
gastrointestinal tract, kidney, brain, and pancreatic α
-cells.(9) Due to this complex pathogenesis, new 
antidiabetic drugs remain necessary to fill the gaps 
in the current T2D treatment.  
 
TYPE 2 IMMUNE RESPONSE AGAINST 
HELMINTH INFECTIONS 
Helminth infections dominantly provoke 
Th2 immune responses via activation of eosino-
phils, macrophage (M2), adaptive Th2 immune cells 
and innate lymphoid cells.(21, 22) Subsequently, in-
nate immune cells along with CD4+ T cells activate 
Th2 response by generating IL-4, IL-5, and IL-13 
that bind to receptors with an IL-4Rα constituent. 
(23, 24) Although basophils do not provide a direct 
defensive function during helminth infection, the 
depletion of basophils trigger a decrease of parasite-
specific IgE, eosinophils, IL-4 production, and 
CD4+ proliferation, which overall amplify the Th2 
response. (25) 
During helminth infection, the Th2 cytokines 
IL-4 and IL-13 modulate signal transducer and acti-
vator of transcription 6 (STAT6).(26, 27) This 
activation inhibits transcription of peroxisome 
proliferator-activated receptor α (PPARα) which 
increase insulin sensitivity.(28) Furthermore, 
eosinophils and macrophages are evident to  protect 
the sensitivity of adipocytes to insulin and to 
maintain metabolic homeostasis of the body.(26)  
A study on the infection of Nippostrongylus 
brasiliensis in obese mouse reported weight-loss 
assigned to IL-13 and STAT-6-dependent and 
independent mechanisms.(29) Furthermore, M2 
polarization and eosinophils that were triggered by 
helminth infection or helminth-derived product lead 
to the decrease of adipocyte size and the increase of 
the white adipose tissue (WAT)-specific insulin 
sensitivity and elevate uptake of peripheral glucose. 
(12) 
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HELMINTHS AND ITS DERIVED PRODUCTS 
IN TYPE 2 DIABETES TREATMENT 
Investigation on the correlation of helminth 
infections or its derived products with T2D has been 
done over the past decenniums. Revealing the 
natural potential of helminth in T2D medication, 
researchers focused on several species namely 
Schistosoma mansoni, Nippostrongylus brasiliens, 
Litomosoides sigmodontis, and Strongyloides ster-
coralis. Some reasearchers also focused on 
analyzing helminth-derived product such as Lewis-
X-containing pentasaccharide called lacto-N-
fucopentaose III (LNFPIII) that is found on 
schistosome egg antigens.(30, 31)  
Schistosoma mansoni 
Parasitic trematode Schistosoma mansoni 
causes intestinal schistosomiasis in humans.(32) S. 
mansoni infection and its derived products reduce 
inflammation and increase glucose tolerance 
through the activation of eosinophils, dendritic cells, 
macrophages, and group 2 innate lymphoid cells.(33) 
Moreover, S. mansoni infection and products also 
enhance the number of Tregs and Th2 cells, as well 
as reduce Th1 and Th17 cells, and therefore is 
effective for T2D treatment.(33) 
The S. mansoni eggs are vital for stimulating 
Th2 response during the infection process. The 
soluble egg antigens (SEA) of S. mansoni activate 
Treg responses as well as Th2-polarized responses, 
which both suppress the Th1 responses development 
(34). The S. mansoni eggs injection into mice 
promotes rapid recruitment of basophils that leads to 
the expression of MHC class II and the exaggeration 
of CD4+ cells proliferation to develop into Th2 
cells.(35) Moreover, the beneficial effects of injected 
SEA in enhancing Th2 responses and maintaining 
metabolic homeostasis were observed in WAT and 
liver of obese mice.(12)  
LNFPIII is a Lewis-X-containing glycan on 
schistosome egg antigens that can further be ex-
plored for treating T2D. Naturally, high concentra-
tion of LNFPIII is found in human breast milk and 
pregnant women urine. LNFPIII is also found as the 
glycan structure of stage-specific embryonic antigen
-1 (SSEA-1) that is expressed on fetal brain tissue. 
(31, 36) Thus, LNFPIII expression is adopted by schis-
tosome parasite in order to decrease the immune 
response of the host to their eggs in gut.(31) Although 
some studies reported that LNFPIII is a schistosome 
glycan (30, 37), Tundup and co-workers argued that 
schistosome literally express Lewis-X trisaccharide, 
an integrated component in the LNFPIII pentasac-
charide. LNFPIII itself is made synthetically as a 
schistosome egg glycan to induce Th2 response.(38)     
LNFPIII induces Th2 responses by triggering 
dendritic cell (DC) maturation via toll-like receptor 
4 (TLR-4).(39) LNFPIII has the ability to increase 
glucose tolerance and insulin sensitivity in 
consequence of IL-10 production that is activated 
by LNFPIII-induced M2 macrophages and DC. The 
IL-10 reduces the inflammation of WAT and 
enhances the sensitivity of adipocytes towards insu-
lin.(30) Endocytosis of LNFPIII is required in the 
alternative activation of M2 macrophages and DC, 
the antigen presenting cells (APCs) (40).   
 
Nippostrongylus brasiliensis 
The hookworm Nippostrongylus brasiliensis 
infection strongly promotes Th2 immune response 
as well as initiates the differentiation of M2 macro-
phages.(41) A study conducted by Wu and co-
workers (2011) proved that the infection of N. 
brasiliensis decreases fasting glucose levels in mice 
with high-fat-diet.(42) Moreover, infection of N. 
brasiliensis increased glucose tolerance and insulin 
sensitivity through a mechanism that is associated 
with white adipose tissue eosinophils.(42) In line 
with Wu and co-workers (2011), Yang and co-
workers (2013) found that infection of N. brasili-
ensis could maintain glucose homeostasis and in-
crease insulin sensitivity by way of Th2 responses 
induction and M2 macrophages activation in adi-
pose tissue. In addition, STAT6 activation by IL-4 
or IL-13 causes the body weight loss and the lipo-
genesis reduction.(29) 
 
Litomosoides sigmodontis 
Litosomoides sigmodontis is a notorious 
nematode model for filariasis infection in laboratory 
murine species.(43) During L. sigmodontis chronic 
infection,  the type 2 immune response is reinforced 
by basophils an thus resulting in the production of 
eosinophils, high amount of IgE, and type 2 
cytokines production.(25) L. sigmodontis infection 
also induces the production of T helper cell-derived 
cytokines such as IFN-γ, IL-4, and IL-5 by CD4+ T 
cells.(25) In addition, a study by Taylor and co 
workers (2009) shows that the formation of CD4(+)
Foxp3(+) Treg cells is rapidly stimulated during L. 
sigmodontis infection.(44) These initial CD4+ T cells 
expressed PPAR-γ, which is required for the insulin 
sensitivity restoration after treatment by an antidia-
betic drug, pioglitazone.(45) L. sigmodontis infection 
as well as L. Sigmodontis antigen administration 
also enhance glucose tolerance and decrease 
epididymal adipose tissue inflammation induced by 
diet in obese mice.(46)  
  
Strongyloides stercoralis 
Strongyloides stercoralis is a nematode that 
causes strongyloidiasis intestinal infection in hu-
mans.(47) A cross-sectional study of 259 Australian 
Aboriginal adults that aimed to examine the relation 
of S. stercoralis infection and T2D shows that 92 
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participants with previous S. Stercoralis infection 
were 61% less likely to be diagnosed with T2D than 
those uninfected.(48) As indicated by the authors, the 
induction of Th2 responses and number of eosino-
phils caused by chronic helminth infection might be 
the possible reason of this finding.(48) The 
infiltration of eosinophils into adipose tissues drive 
the recruitment and maintenance of M2, the 
alternatively activated macrophages that will 
enhance the insulin sensitivity through regulatory T 
cells (Treg) and IL-10.(26, 42)  
A cohort study in 259 Australian Aboriginal 
adults shows that treatment for    S. stercoralis 
ameliorate glycemic control and significantly 
enhance HbA1c in patients with pre-existing T2D.
(49) Meanwhile, treatment for S. stercoralis in 
patients without T2D exhibits significant effects on 
the development of T2D and glucose intolerance.(49) 
A current study also shows that S. stercoralis 
infection has a preventive effect in T2D since this 
infection is associated with diabetes-related 
parameters including cytokine, hormonal, and 
glycemic.(50) Yet, more convincing data as well as 
plausible molecular mechanisms are needed in order 
to prove the beneficial effect of S. stercoralis in T2D 
treatment. 
 
HELMINTH AND ITS DERIVED PRODUCTS: 
A FUTURE HOPE 
The explorations of helminth infections and 
its derived products in inducing immune response, 
particularly the Th2 immune response, have been 
done in the past few decades.(21, 22) The Th2 immune 
response is considered to play a potential role in 
metabolic process including insulin sensitivity and 
glucose metabolism.(26, 28, 29) Despite being relatively 
less studied compared to T1D, some crucial findings 
about the correlation of helminth infection and T2D 
appeared to be very promising in T2D treatments  
development.  
The roles of helminth infection in 
maintaining glucose homeostasis and enhancing 
insulin sensitivity in T2D and obese subjects have 
been demonstrated in in vivo studies in mice.(12, 28, 29, 
42) Although there is still limited evidence about the 
beneficial effects of helminth infection and its 
antigens in human, these worthwhile findings could 
be a stepping stone in the development of helminth 
as medicinal agents in T2D treatment for patients.  
There is a cross-sectional study in China 
showing the correlation between schistosome 
infections with lessen prevalence of diabetes and 
better glucose homeostasis. In addition, there is an 
ongoing cluster-randomized placebo controlled 
study will be conducted in Indonesia to figure out 
the effect of helminth infection in insulin sensitivity. 
These two studies are predicted to fill the 
knowledge gaps in the potential role of helminth in 
T2D medication. Besides, information about 
helminth-related agents such as its efficacy in 
various group of patients (e.g. gender, age, ethnic, 
and gender) and its effectiveness compared to 
antidiabetics drugs on the market are essentially 
needed.(51) 
Moreover, one of the helminth-derived 
product that might be promising for new 
antidiabetic agent is SEA. LNFPIII found in SEA 
shows positive effects in inducing Th2 responses 
and improving insulin sensitivity.(30, 39) Because 
LNFPIII is possible to be synthetically made as 
single compound, this antigen will be more feasible 
to be developed as a new therapeutic agent since the 
dosage forms,  the therapeutic and toxic dose, as 
well as the metabolism of single compound will be 
easier to be evaluated. Beside SEA, there are other 
S. mansoni egg components that can activate Th2 
response namely Omega-1 and interleukin-4-
inducing principle from S. mansoni egg (IPSE/alpha
-1).(52) Omega-1 is a T2 ribonuclease and is one of 
the most abundant SEA component that induces 
Th2 polarization through DC conditioning.(53) 
Omega-1 is internalized by DC  via the mannose 
receptor (MR) and its activity depends on RNase 
activity and glycosylation.(54) Omega-1 has a Galβ1-
4(Fucα1-3)GlcNAc (Lewis-X) motif as the major 
antenna and also other terminal glycans such as 
GalNAc_1-4(FucR1-3)GlcNAc (LDN-F), dyfuco-
sylated Galβ1-4GlcNAc (LacNAc,LN) and Gal-
NAcβ1-4GlcNAc (LacdiNAc, LDN).(55) Lewis-X is 
an important feature of omega-1 that plays a role in 
Th2 polarization.(55)     
Similar as omega-1, IPSE/alpha-1 is also one 
of the most plentiful glycoproteins that are secreted 
by S. mansoni eggs.(56) IPSE/alpha-1 has almost an 
identical glycosylation pattern with omega-1 as both 
have Lewis-X antenna and dyfucosylated LN and 
LDN.(57) Apart from similarity Lewis-X glycans 
pattern between IPSE/alpha-1 and omega-1, IPSE/
alpha-1 is unable to promote a strong Th2 polariza-
tion through DC conditioning.(55) IPSE/alpha-1 acti-
vates basophils and enhances their expression of IL-
4 and IL-13 cytokines, which are essential for Th2 
immune responses.(58)      
The ability of IPSE/alpha-1 and omega-1 in 
activating the host Th2 immune responses through 
IL-4 and DC activation escalate these antigens 
probability to be a part of T2D medication. 
Moreover, Lewis-X, helminth glycan that is found 
in terminal trisaccharide of LNFPIII and is 
expressed on core-dyfucosylated N-glycans of 
IPSE/alpha-1 also promote anti-inflammatory state 
via alternative activation of APCs.(59) Thus, both 
IPSE/alpha-1 and omega-1 are potential as 
immunotherapeutics to treat inflammatory-related 
diseases including T2D and obesity.  
S. mansoni and its SEA so far receive the 
main limelight to be developed as a new treatment 
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for treating T2D. However, limited studies are avail-
able to explore the same therapeutic possibility from 
other helminths such as L. sigmodontis and N. 
brasiliensis. Although relatively shaded, these hel-
minths have the potential to develop into new drugs 
due to their ability to provoke Th2 response via IL-4 
activation.(25, 29) In addition, a laboratory model for 
the human whipworm Trichuris trichuria called 
Trichuris muris,  should also be further considered 
in the quest for developing drugs for T2D (60) as this 
helminth induces strong Th2 responses through the 
IL-4/STAT6 pathway.(61) Finally, considering that 
helminth infection strongly induces Th2 responses 
and huge diversity of these phyla, there is optimism 
in discovering more promising species and their 
derived products to be developed as 
immunotherapeutic for T2D treatment. 
 
CONCLUSION  
Our review summarized the potential of hel-
minths to be applied in treating  type 2 diabetes via 
induction of type 2 immune response. To date, 
Schistosoma mansoni (including its SEA compo-
nents such as LNFPIII, IPSE/alpha-1, and omega-1), 
Nippostrongylus brasiliensis, and Litosomoides 
sigmodontis seem to be the most promising helminth 
candidates as therapeutic drugs given their capacity 
to maintain glucose homeostasis and increasing 
insulin sensitivity. While, other potential helminths 
such as Trichuris muris and Strongyloides 
stercoralis still need further investigation.  
Despite some promising evident of helminth 
and helminth derived products to be applied in treat-
ing T2D patients, a number of considerations should 
be taken into account. Firstly, patients with T2D 
cannot be deliberately exposed with helminths only 
for improving their metabolic disorder. Secondly, 
the administration, dosage, and duration of helminth 
therapy should be examined carefully with regard to 
safety, side effects and toxicity to treat T2D pa-
tients.(51) At the first place, the effect of helminth 
infection on T2D patients should be confirmed. Sub-
sequently, helminth’s components or antigens that 
are responsible for the therapeutic effect should also 
be identified. Once these specific compounds are 
identified, efficacy of these molecules as new thera-
peutic agents can be explored. Finally, extensive in 
vivo studies are crucial to further generate unequiv-
ocal evidence in developing helminth and helminth-
derived products therapeutic to treat type 2 diabetes 
in humans. 
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